The Farnesyl Pyrophosphate Synthase pipeline drugs market research report outlays comprehensive information on the Farnesyl Pyrophosphate Synthase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Farnesyl Pyrophosphate Synthase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Musculoskeletal Disorders, and Oncology which include the indications Osteoporosis, Post Menopausal Osteoporosis, Bone Metastasis, and Metastatic Breast Cancer. It also reviews key players involved in Farnesyl Pyrophosphate Synthase targeted therapeutics development with respective active and dormant or discontinued products.
The Farnesyl Pyrophosphate Synthase pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 1, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Farnesyl Pyrophosphate Synthase overview
Farnesyl pyrophosphate synthase (FDPS) is an important enzyme in isoprenoid biosynthesis that catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FDPS catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.
For a complete picture of Farnesyl Pyrophosphate Synthase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
